U.S. Markets open in 2 hrs

Biocept's Liquid Biopsy Test for ESR1 Biomarker Detection to be Featured in Poster Presentation at the 2019 AACR Annual Meeting

Analytical validation of liquid biopsy test for ESR1 mutations offers potential clinical utility by identifying biomarkers that may drive acquired resistance to hormone therapy in breast cancer

SAN DIEGO, March 4, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that its abstract demonstrating the ability of the Company's Target Selector™ liquid biopsy test to detect ESR1 mutations with high sensitivity has been accepted for a poster presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting being held March 29-April 3, 2019 at the Georgia World Congress Center in Atlanta.

Biocept Logo (PRNewsFoto/Biocept, Inc.)

"ESR1 mutation testing by means of liquid biopsy affords testing of a treatment predictive biomarker in patients with hormone receptor positive metastatic breast cancer, the subtype present in the majority of patients," said Lee Schwartzberg, MD, FACP, Executive Director of West Cancer Center and Professor of Medicine, University of Tennessee Health Science Center. "This method of testing can offer the promise of monitoring patients for the emergence of resistance to certain types of endocrine therapy in a timely manner using a simple blood sample."

Details for the poster presentations are as follows:

Title: Validation of highly sensitive ctDNA assays for ESR1 resistance mutations with the NGS Target Selector™ enrichment technology
Session Category/Title: Clinical Research/Current Developments in Non-invasive Biomarkers for Assessment of Cancer 3
Session Date and Time: Monday, April 1, 2019; 1:00 p.m. - 5:00 p.m. Eastern time
Location: Georgia World Congress Center, Exhibit Hall B

"Our poster at the AACR conference, once again, highlights the performance and versatility of our proprietary liquid biopsy technology. This year's poster presentation features the expansion of our high-sensitivity Target Selector™ assay platform to encompass emerging biomarkers, like ESR1 alterations, which are being used for the development of new targeted treatments for breast cancer," said Michael Nall, President and CEO of Biocept.  "We believe the validation of this assay to detect actionable biomarkers associated with metastatic breast cancer can provide information to aid in therapy selection and in monitoring patient response to therapy, as well as potentially improving patient outcomes."

About Biocept

Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.  The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, the potential clinical utility of our proprietary technology platform and our ability to broaden the use of our proprietary technology platform, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.

Contact:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100

 

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/biocepts-liquid-biopsy-test-for-esr1-biomarker-detection-to-be-featured-in-poster-presentation-at-the-2019-aacr-annual-meeting-300804845.html